Impact of tumor progression on cancer incidence curves

Cancer Research

Volumn 73, Issue 3, 2013, Pages 1086-1096

  Luebeck, E Georg ^a,b   Curtius, Kit ^c   Jeon, Jihyoun ^b   Hazelton, William D ^a  

^a Division of Basic Sciences   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER MODEL; CANCER SURVIVAL; CELL EXPANSION; COLORECTAL CANCER; DATA ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; GROWTH RATE; MALIGNANT TRANSFORMATION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MUTATION RATE; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TUMOR PROMOTION;

CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; INCIDENCE; MATHEMATICS; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84873453377     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2198     Document Type: Article

References (48)

1. Meza R, Jeon J, Moolgavkar SH, Luebeck EG. Age-specific incidence of cancer: phases, transitions, and biological implications. Proc Natl Acad Sci U S A 2008;105:16284-9.
2. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A 2002;99: 15095-100.
3. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control 2006;17:971-81.
4. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United kingdom: evidence of right-to left-sided biological gradients with implications for screening. Cancer Res 2010;70:5419-29.
5. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence SEER 9 Regs Limited-Use, Nov 2009 Sub (1973-2007) (Katrina/Rita Population Adjustment)- linked to county attributes-total U.S., 1969-2007 counties. April 2010, based on the November 2009 submission ed: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. [cited 2012 Mar 13]. Available from: http://seer. cancer.gov/.
6. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
7. Moffett BF, Baban D, Bao L, Tarin D. Fate of clonal lineages during neoplasia and metastasis studied with an incorporated genetic marker. Cancer Res 1992;52:1737-43.
8. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007;3:e225.
9. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
10. Karaman A, Kabalar ME, Binici DN, Ozturk C, Pirim I. Genetic alterations in gastric precancerous lesions. Genet Couns 2010;21:439-50.
11. Norfadzilah MY, Pailoor J, Retneswari M, Chinna K, Noor LM. P53 expression in invasive pancreatic adenocarcinoma and precursor lesions. Malays J Pathol 2011;33:89-94.
12. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010;107:246-51.
13. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Seshat K, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102(Pt 1): 1220-8.
14. Moore JH, Lesser EJ, Erdody DH, Natale RB, Orringer MB, Beer DG. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 1994;56:487-93.
15. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91: 2087-95.
16. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
17. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
18. Harris TE. The theory of branching processes. New York: Dover Publications, Inc.; 1989.
19. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
20. Fakir H, Tan WY, Hlatky L, Hahnfeldt P, Sachs RK. Stochastic population dynamic effects for lung cancer progression. Radiat Res 2009;172:383-93.
21. Fakir H, Hofmann W, Sachs RK. Modeling progression in radiationinduced lung adenocarcinomas. Radiat Environ Biophys 2010;49: 169-76.
22. Dewanji A, Moolgavkar SH, Luebeck EG. Two-mutation model for carcinogenesis: joint analysis of premalignant and malignant lesions. Math Biosci 1991;104:97-109.
23. Little MP. Are twomutations sufficient to cause cancer? Somegeneralizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon, and Knudson, and of the multistage model of Armitage and Doll. Biometrics 1995;51:1278-91.
24. Little MP, Heidenreich WF, Li G. Parameter identifiability and redundancy in a general class of stochastic carcinogenesis models. PLoS ONE 2009;4:e8520.
25. Heidenreich WF, Luebeck EG, Moolgavkar SH. Some properties of the hazard function of the two-mutation clonal expansion model. Risk Anal 1997;17:391-9.
26. Ronkainen J, Aro P, Storskrubb T, Johansson S, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
27. Teixeira CR, Haruma K, Teshima H, Yoshihara M, Sumii K, Kajiyama G. Endoscopic therapy for gastric cancer in patients more than 80 years old. Am J Gastroenterol 1991;86:725-8.
28. Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999;71:140-6.
29. Bolin S, Nilsson E, Sjodahl R. Carcinoma of the colon and rectumgrowth rate. Ann Surg 1983;198:151-8.
30. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-46.
31. Luebeck EG, Buchmann A, Stinchcombe S, Moolgavkar SH, Schwarz M. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on initiation and promotion of GST-P-positive foci in rat liver: a quantitative analysis of experimental data using a stochastic model. Toxicol Appl Pharmacol 2000;167:63-73.
32. Moolgavkar SH, Luebeck EG, de Gunst M, Port RE, Schwarz M. Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments-I. Single agent regimen. Carcinogenesis 1990;11: 1271-8.
33. Luebeck EG, Heidenreich WF, Hazelton WD, Paretzke HG, Moolgavkar SH. Biologically based analysis of the data for the Colorado uranium miners cohort: age, dose and dose-rate effects. Radiat Res 1999;152: 339-51.
34. Moolgavkar SH, Knudson AG. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981;66:1037-52.
35. Moolgavkar SH, Venzon DJ. Two-event models for carcinogenesis: incidence curves for childhood and adult tumors. Math Biosci 1979;47:55-77.
36. Holford TR, Zhang Z, McKay LA. Estimating age, period and cohort effects using the multistage model for cancer. Stat Med 1994;13: 23-41.
37. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
38. Brentnall TA, Lai LA, Coleman J, Bronner MP, Pan S, Chen R. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS ONE 2012;7:e30219.
39. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8.
40. Yachida S, Zhong Y, Patrascu R, Davis MB, Morsberger LA, Griffin CA, et al. Establishment and characterization of a new cell line, A99, from a primary small cell carcinoma of the pancreas. Pancreas 2011;40: 905-10.
41. Luebeck EG. Cancer: genomic evolution of metastasis. Nature 2010;467:1053-5.
42. Moolgavkar SH. Carcinogenesis models: an overview. Basic Life Sci 1991;58:387-96.
43. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis: population-based model for colon cancer. J Natl Cancer Inst 1992; 84:610-8.
44. Heidenreich WF, Luebeck EG, Moolgavkar SH. Effects of exposure uncertainties in the TSCE model and application to the Colorado miners data. Radiat Res 2004;161:72-81.
45. Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control 2008;19:317-28.
46. Xu XL. The biological foundation of the Gompertz model. Int J Biomed Comput 1987;20:35-9.
47. Brosnan JA, Iacobuzio-Donahue CA. A new branch on the tree: nextgeneration sequencing in the study of cancer evolution. Semin Cell Dev Biol 2012;23:237-42.
48. Martens EA, Kostadinov R, Maley CC, Hallatschek O. Spatial structure increases the waiting time for cancer. New J Phys 2011;13:1-22.